Background: Proton Pump Inhibitors (PPI) are observed to be great healer in gastroesophageal refl ux disorder (GERD) and duodenal ulcer. Quantifi cation of the drugs in human plasma by validated bioanalytical method are very important to determine pharmacokinetic parameters for undergoing comparative study with standard available formulations to make the newer one commercially available. Objective: The objective of this study was to determine the relative bioavailability of Ilaprazole, a novel PPI comparing the test formulation to the reference one according to standard regulatory guidelines. Materials and Methods: The bioequivalence of two tablet formulations, one as reference and other as test containing 10 mg of ilaprazole [CAS No. 172152-36-2] was studied in 12 healthy Indian volunteers. This was a single dose, twoperiod and randomized crossover study separated with a washout period of one week. Plasma samples for pharmacokinetic analysis were collected before dosing and at pre-specifi ed time points after dosing. The concentration of ilaprazole in plasma was determined by a validated HPLC-UV method using theophylline as internal standard. The formulations were compared using the parameters Area under the plasma concentration-time curve (AUC 0-t ), Area under the plasma concentration-time curve from zero to infi nity (AUC 0-∞ ), Peak plasma concentration (C max ), and time to reach peak plasma concentration (t max ). Results: Mean AUC 0-t of test and reference product were calculated to be 2627.793 ± 154.989 ng h ml −1 and 2555.905 ± 225.916 ng h ml
Introduction
Proton pump inhibitors (PPIs) have been used therapeutically for many years and shown great efficacy in accelerating ulcer 3-methyl)-2-pyridinyl]methylsulfinyl-5-(1H pyrrol-1-yl)-1H-benzimidazole[CAS No. 172152-36-2], a novel PPI, is found to significantly prevent the development of reflux oesophagitis and gastric secretion in a dose-dependent manner as an outcome of one clinical study on patients with gastroesophageal reflux disorder (GERD) and the newer PPI has also shown efficacy in treatment of duodenal ulcer in a detailed comparative study on patients with DU. [1, 2] Currently, researches are focused on more potent PPIs. Some preclinical studies have shown that ilaprazole might be such a new substitute. [3] It is usually rapidly absorbed after oral administration. Ilaprazole might be dominantly metabolized in the liver by CYP3A and partly by CYP2C19. In all, in vitro and in vivo evidence supporting CYP3A and CYP2C19 both the types display roles on the systemic elimination of ilaprazole, which has been demonstrated by the study of Y. Li et al.[2008] . [4] Previous work done on bioequivalence study of ilaprazole by validated LCMS/MS method have shown the values of t 1/2 , AUC 0-∞ , C max are 4.5 h, 500-900 ng h mL
, 90-102 ng mL
, respectively, on ilaprazole 5 mg oral administration to healthy human volunteers. The drug is primarily excreted in the urine as drug metabolites and unchanged drug to some extent. [5] A rapid, sensitive, cost effective high performance liquid chromatography (HPLC) method with ultraviolet (UV) detection technique has been developed for the pharmacokinetic study of ilaprazole in human plasma. The method was reproducible and validated as per the guidelines.
Bioavailability and bioequivalence issues have been an increasing concern to drug regulatory authorities for assessment of the safety and efficacy of drug products. As the number of synonymous drug products increase, special attention in bioavailability issues becomes a major concern. [6] Bioequivalence of two formulations of the same drug comprises equivalence with respect to the rate and extent of absorption while the area under plasma concentration-time curve (AUC) generally serves as the characteristic of the extent of absorption. [7] No single parameter reliably measures the rate of absorption. For instance, the maximal drug concentration (C max ) has been widely used, but it depends more on the fraction absorbed than the rate of absorbed; the time of maximal drug concentration (t max ) depends on both absorption and elimination rates. [8] The objective of the present study was to evaluate the relative bioavailability of tablet ilaprazole (containing ilaprazole enteric-coated tablet 10 mg) in comparison with Noltec tablet 10 mg (containing ilaprazole enteric-coated tablet 10 mg) in 12 healthy male adult human Indian volunteers under fasting condition.
Materials and Methods

Materials and reagents
Acetonitrile (ACN), ethyl acetate were purchased from Merck (MERCK India Ltd., Mumbai) and Spectrochem (Spectrochem Pvt. Ltd., Mumbai, India) supplied potassium dihydrogen phosphate buffer. All solvents used were of HPLC grade. Other chemicals and reagents of analytical grade were used throughout the study. HPLC grade water with a resistivity of 18 MΩ was taken from a Milli-Q gradient system of Millipore (Elix, Milli-Q A10 Academic, Bedford, MA, USA). The pooled blank human plasma with EDTA-K 3 anticoagulant was collected from Clinical Pharmacological Unit (CPU) of Bioequivalence Study Centre, Jadavpur University, Kolkata (India).
Products studied
Test product
Tablet Ilaprazole (containing ilaprazole enteric-coated tablet 
Study design
Healthy, normal twelve Indian human volunteers were enrolled for this study. The volunteers were clinically examined by the doctor and after confirming that they did not have any history of smoking, alcohol consuming, and participation on any other study in previous 2-3 months, they were included in the study. Generally, the informed consent process of the volunteers was followed as per the protocol after obtaining approval by the Drugs Controller General of India (DCGI), New Delhi and Institutional Ethical Committee (IEC) of Jadavpur University, Kolkata (India). Average age, height, and weight of the volunteers were 27.92 ± 5.12 years, 171.28 ± 6.85 cm, and 66.43 ± 5.21 kg, respectively. Informed consent was obtained from all the subjects prior to the start of this randomized, single dose, fasting, two-period, two-sequence crossover study with one-week washout period. [9, 10] The study was carried out in compliance with Good Clinical Practice (GCP) and Declaration of Helsinki.
Drug administration and sample collection
All 12 volunteers, as stated before under the heading "Study design," were assembled in the CPU. After overnight fasting of 10 h, they received their individual drug as per randomization. They received either the test drug or the reference drug with 240 mL of water. The volunteers must be ensured that they did not consume caffeinated or alcoholic beverages at least 72 h prior to drug administration or during the study days. Usually, the sampling time should extend to at least three terminal elimination half-lives of the active ingredient. The time periods between sampling should not exceed one terminal half-life. [11, 15] A total of 14 blood samples were collected at 0 h (before drug administration) and 0.5, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 6.00, 10.00, 18.00, 24.00, and 36.00 h (after drug administration) in the test tubes containing EDTA at each time point. Breakfast, lunch, and dinner were provided after 4 h, 8 h, and 14 h, respectively, after drug ingestion. On study days, volunteers were permitted normal activities, excluding strenuous exercise.
Collected blood samples were centrifuged immediately; plasma was separated and stored in frozen condition at −20 0 C with appropriate labeling of volunteer code no., study date, and collection time till analysis.
Sample preparation
In a stoppered test tube, 1.0 mL of plasma was taken. To this 0.1 mL of Internal Standard (IS; theophylline 2000 ng mL 
Chromatographic conditions
Processed and reconstituted plasma samples were analyzed for ilaprazole by HPLC. The HPLC system was of Shimadzu, Japan with a BDS Hypersil C 18 (250 × 4.6 mm, 5 μ particle size) column. The wave length for detection was 274 nm and Spinchrom integrating software was used. Mobile phase consisting of ACN with 10 mM potassium dihydrogen phosphate (pH 7) in 20:80 (v/v) ratio with a 1.0 mL/min flow rate were set. The method was validated as per the standard guidelines. [13] Calibration Serial dilutions (100-5000 ng mL ) of the ilaprazole stock solution were prepared using mobile phase. Each of these dilutions (0.1 mL) was added to 0.9 mL screened plasma to furnish concentrations in the range 10-500 ng mL . These samples were processed as stated previously and analyzed by HPLC. The ratio of areas of the ilaprazole and theophylline (IS) peak were plotted against the concentration of ilaprazole [ Figure 1 ].
Method Validation
The method was validated for accuracy, precision, sensitivity, recovery, linearity, and stability in accordance with current updated version of FDA guidelines, using theophylline as IS. [12] Linearity, precision, and accuracy were tested by analysis of five batches of spiked plasma quality-control (QC) samples. Each batch of spiked plasma samples included one complete set of calibration standards (comprising six different concentrations, blank, and blank with internal standard) and QC samples at low (30 ng mL−1; LQC), middle (200 ng mL−1; MQC), and high (400 ng mL−1; HQC) concentrations.
Within-run and between-run precision values (%CV) ranged from 5.062% to 9.570%. Within-run and between-run accuracy values (% nominal) were 92.40% for LQC, 94.36% for MQC, and 93.22% for HQC samples. Recovery after extraction was calculated to be 95.69-98.32% by comparing the peak areas of the plasma LQC, MQC, and HQC samples to the absolute peak area of the unextracted standards containing the same concentrations of ilaprazole. The stability of LQC, MQC, and HQC samples were determined after three freeze thaw cycles comparing against freshly thawed samples of the same concentration. The stability of ilaprazole ranges between 98.56-98.97% after three cycles.
Application to comparative pharmacokinetics study
The validated HPLC-UV method is successfully applied to the bioequivalence study of ilaprazole evaluating the relative bioavailability of tablet ilaprazole (containing ilaprazole enteric-coated tablet 10 mg) in comparison with Noltec 
Pharmacokinetic analysis
Plasma levels of ilaprazole 10 mg (both test and reference) for every volunteer at each time point were plotted to obtain time-plasma concentration curves for the study preparations. The mean pharmacokinetic parameters of bioavailability calculated for this single-dose study were maximum plasma concentration (C max ), time to maximum plasma concentration (t max ), the area under plasma concentration vs. time curve (AUC 0-t ), the area under plasma concentration vs. time curve 0 to infinity (AUC 0-∞ ), elimination half life (t 1/2 ), and elimination rate constant (K el ) from the analytical data.
The last seven quantifiable levels were used to determine K el . AUC 0-t was calculated from the measured levels, from time zero to the time of last quantifiable level, by the linear trapezoidal rule. AUC 0-∞ was calculated according to the following formula: AUC 0-∞ = AUC 0-t + C last /K el , where C last is the last quantifiable plasma level. t 1/2 was calculated using the conventional formula 0.693/K el . Tolerability of ilaprazole was assessed by monitoring and subjects interview regarding the potential presence of adverse events.
Statistical analysis
For each subject, descriptive statistics were used to summarize the estimated pharmacokinetic parameters. For the purpose of bioequivalence analysis, AUC 0-t , AUC 0-∞ , and C max values were considered primary variables. Their log-transformed data were analyzed by an analysis of variance (ANOVA), including treatment, period, and subject. The bioequivalence analysis was made according to guidance of Committee for Proprietary Medicinal Products (CPMP): "test" product was considered bioequivalent to "reference" product if 90% confidence interval (CI) for the ratio between each parameter fell within the predetermined equivalence range of 80-125%. [14] 
Results
The maximum plasma concentrations of 328.640 + 57.710 ng mL −1 (C max ) at the time 4.667 + 0.985 h (t max ) were found for the reference product whereas the C max and T max for the test product containing 10 mg of Ilaprazole were 347.459 + 48.175 ng mL −1 and 4.833 + 1.030 h, respectively.
Administration of the Reference preparation, Noltec Tablet 10 mg, produced the AUC 0-t 2555.905 ± 225.916 ng hr mL −1 , whereas administration of the test preparation produced AUC 0-t 2627.793 ± 154.989 ng hr mL −1 [ Table 1 ]. Mean plasma concentration versus time curves after administration of "reference" and "test" products to healthy subjects are shown in Figure 2 . The plasma t 1/2 for reference and test preparations was 5.386 ± 0.767 h and 5.501 ± 0.689 h, respectively.
On the basis of comparison of the AUC 0-t for ilaprazole after single-dose administration, the relative bioavailability of the test preparation ilaprazole was 102.81% that of the reference preparation, Noltec Tablet 10 mg The 90% confidence interval for C max , values is represented in the Table 1 . The observed t max values for "test" product were within the acceptable limits (±20% of the mean values of "reference" product).
Discussion
The aim of bioequivalence study is to assure interchangeability between an innovator and a generic formula in terms of efficacy and safety. When a pharmacological effect is difficult to measure, the plasma levels of a drug may be used as an indicator of clinical activity. Therefore, ilaprazole plasma levels obtained in this study suggest an equal clinical efficacy of the two brands tested and provide pharmacokinetic data from Indian population. The developed bioanalytical method for the determination of ilaprazole in human plasma was sensitive, fast, and accurate.
It has been observed from the present study that the subjects formed a homogeneous population in terms of age, weight, and body mass index. Ilaprazole was well-tolerated, and there were no dropouts as well as no discomforts after administration to the volunteers.
From the literature review, it has been learnt that ilaprazole represents itself in two enantiomers in the body, i.e., d-ilaprazole and l-ilaprazole but both enantiomers possess the PPI activity. Therefore, imbalance between these two forms does not result in failure of drug action. This is proved from the successful application of this non-enantiomer selective HPLC-UV method on the pharmacokinetic study. Almost equal elimination rate, t 1/2 , and t max of the reference and test products indicate bioequivalence, and it shows no effect of the variation in pharmaceutical formulation on the pharmacokinetic parameters of the drug.
Conclusion
The 90% CI of C max , AUC 0-t and AUC 0-∞ were in the acceptable range of 80-125% ANOVA (subject, period, treatment) was applied to the C max , ln C max , AUC 0-t , and ln AUC 0-t values. There was no statistically significant difference for the treatment values. Both formulations were equal in terms of rate and extent of absorption. On the basis of pharmacokinetic parameters studied, it can be concluded that the "test" product is bioequivalent with the "reference" product.
